NAMS
NewAmsterdam Pharma Company N.V.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
5.71
P/S
174.33
EV/EBITDA
-14.17
DCF Value
$3.47
FCF Yield
-3.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.7%
Operating Margin
-1002.9%
Net Margin
-905.7%
ROE
-27.5%
ROA
-26.5%
ROIC
-33.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $32.0K | $-74.9M | $-0.65 |
| FY 2025 | $22.5M | $-203.8M | $-1.75 |
| Q3 2025 | $348.0K | $-72.0M | $-0.61 |
| Q2 2025 | $19.1M | $-17.4M | $-0.15 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
NL
Exchange
NASDAQ
Beta
0.13
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.